Back to top
more

BioRad Laboratories (BIO)

(Delayed Data from NYSE)

$272.18 USD

272.18
309,158

-4.62 (-1.67%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $272.29 +0.11 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.

Zacks Equity Research

Zacks Industry Outlook Highlights: Abbott Lab, Bio-Rad Lab and Hill-Rom Holdings

by Zacks Equity Research

Zacks Industry Outlook Highlights: Abbott Lab, Bio-Rad Lab and Hill-Rom Holdings

Trina Mukherjee headshot

3 Stocks to Capitalize on the Buoyant Medical Products Industry

by Trina Mukherjee

Despite the COVID-19 pandemic induced challenges, rising demand for IVD coupled with dependence on AI & Robotics should lend support to the Zacks Medical-Products industry. ABT, BIO and HRC are well-poised to gain from the prospects.

Zacks Equity Research

Bio Rad (BIO) Grows Internationally on New Product Launches

by Zacks Equity Research

Strength in Bio Rad's (BIO) key product lines across major geographic regions buoys optimism.

Zacks Equity Research

Here's Why You Should Invest in Bio-Rad (BIO) Stock Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO) on strength in its key product lines and raised 2021 guidance.

Zacks Equity Research

Is Bio-Rad Laboratories (BIO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Bio-Rad Laboratories (BIO) and Fullgent Genetics (FLGT) have performed compared to their sector so far this year.

Zacks Equity Research

Here's Why You Should Add Chemed (CHE) to Your Portfolio Now

by Zacks Equity Research

Robust performance across the Roto-Rooter segment and sequential growth in VITAS admissions are driving the top line for Chemed (CHE).

Zacks Equity Research

NuVasive (NUVA) Q3 Earnings Miss Estimates, 2021 Guidance Down

by Zacks Equity Research

NuVasive (NUVA) reported lower-than-expected earnings and revenues with COVID-led headwinds and healthcare staffing shortages dampening the Q3 top-line growth.

Zacks Equity Research

IDEXX (IDXX) CAG Placement Grows Globally, LPD Disappoints

by Zacks Equity Research

IDEXX' (IDXX) global Reference Lab businesses are robust driven by high same-store volume growth with strong gains across testing categories.

Zacks Equity Research

Nevro (NVRO) Q3 Earnings Miss Estimates, Revenues Surpass

by Zacks Equity Research

Nevro (NVRO) reported wider-than-expected loss during the third quarter with a year-over-year decline in revenues across U.S. and international businesses.

Zacks Equity Research

Integra (IART) Q3 Earnings Top Estimates, 2021 EPS View Up

by Zacks Equity Research

Integra (IART) reports better-than-expected earnings and revenues with robust demand for the company's products driving the top line in third-quarter 2021.

Zacks Equity Research

Recent Price Trend in Bio-Rad (BIO) is Your Friend, Here's Why

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Bio-Rad (BIO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

Bio-Rad (BIO) Q3 Earnings Surpass Estimates, 2021 View Raised

by Zacks Equity Research

Strength in the Life Science and Clinical Diagnostics segments drove Bio-Rad's (BIO) revenues in the third quarter.

Zacks Equity Research

Bio-Rad Laboratories (BIO) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Bio-Rad (BIO) delivered earnings and revenue surprises of 61.30% and 11.33%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Recovery in Clinical Diagnostics arm and strong growth in Droplet Digital PCR platform are expected to have contributed to Bio-Rad's (BIO) Q3 results.

Zacks Equity Research

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why You Should Retain Bio-Rad (BIO) Stock For Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO) on solid international market performance and raised 2021 guidance.

Zacks Equity Research

Hologic (HOLX) Launches Novodiag System for On-Demand Testing

by Zacks Equity Research

Hologic (HOLX) introduces the Novodiag system in Europe for on-demand testing of infectious diseases and antimicrobial resistance.

Zacks Equity Research

Bio Rad (BIO) Global Growth Strong, Expenses Continue to Rise

by Zacks Equity Research

Bio Rad (BIO) is witnessing strong growth in the biopharma market, riding on the Droplet Digital PCR platform.

Zacks Equity Research

Bio-Rad (BIO) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

Bio-Rad (BIO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Bio-Rad Laboratories (BIO) Is Up 0.05% in One Week: What You Should Know

by Zacks Equity Research

Does Bio-Rad Laboratories (BIO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO) on solid international market performance and raised 2021 guidance.

Zacks Equity Research

HealthEquity (HQY) Q2 Earnings & Revenues Beat Estimates

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs and records robust Interchange revenues in the second quarter of fiscal 2022.

Zacks Equity Research

Cooper Companies (COO) Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Cooper Companies' (COO) fiscal third-quarter earnings reflect solid segmental performance.

Zacks Equity Research

Patterson Companies (PDCO) Q1 Earnings & Revenues Top Estimates

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal first-quarter 2022 results benefit from strong segmental performance.

Zacks Equity Research

What Makes Bio-Rad (BIO) a Good Fit for "Trend Investing"

by Zacks Equity Research

Bio-Rad (BIO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.